None listed
Conditions
Interventions
Medical Device : This study will recruit 40 patients with Psoriasis Vulgaris. In the upper extremities, lower extremities, and trunk of each patient, 2 bilateral dry skin lesions with similar size and
Sponsors
Dongshin University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants should satisfy all following criteria; 1) Male or female patients aged 19-70 at the screening visit. 2) Patients with moderate psoriasis of the trunk and extremities that can be treated topically that has lasted at least 6 months 3) Patients with 2 Psoriasis Vulgaris lesions that are bilateral and have similar size and severity in the upper extremities, lower extremities, and trunk. 4) Patients who can read and write Korean and voluntarily submitted written consent with their signature.
Exclusion criteria
Exclusion criteria: Patients who satisfy any criterion of the followings cannot participate in this study; 1) Patients with active, growing or spreading psoriasis lesions 2) Patients with other inflammatory skin conditions in the psoriatic lesion area that may interfere with evaluation (e.g., atopic dermatitis, contact dermatitis, ringworm) 3) Patients who have used topical treatments on psoriatic lesions within 7 days of the screening visit (corticosteroids, vitamin D analogs, retinoids, PDE4 inhibitors, salicylic acid, pimecrolimus, tacrolimus) 4) Patients using systemic treatments for psoriasis within 4 weeks of the screening visit (methotrexate, retinoids, PDE4 inhibitors, corticosteroids (excluding inhaled, nasal, ear, or ocular), cyclosporine) 5) Other severe comorbidities (e.g., heart diseases, kidney diseases, liver diseases, respiratory diseases, malignancy, immunodeficiency, etc.) tdeemed inadequate by the principal investigator; the abnormality criteria for liver function is defined as aspartate transaminase (AST) or alanine transaminase (ALT) level 5 times higher than the upper limit of the analyzed institution, and those for renal function is defined as 3 times higher than the upper limit of the analyzed institution. 6) Allergy to adhesives. 7) Pregnant, lactating women, or women planning pregnancy. 8) Others deemed inadequate by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mPASI(modified Psoriasis Area Severity Index) | — |
Secondary
| Measure | Time frame |
|---|---|
| Pruritus visual analogue scale (VAS);Physician’s Global Assessment (PGA);Dermatological Life Quality Index(DLQI);EQ-5D version (EQ-5D-5L) score | — |
Countries
Korea, Republic of
Contacts
Public ContactSoo-Yeon Park
Dongshin University
Outcome results
None listed